GlobeNewswire·Oct 10, 2026, 8:00 AM ET

vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026

vTv Therapeutics announced research presented by CMO Thomas Strack, M.D., Ph.D., at the Breakthrough T1D Clinical & Research Congress regarding hypoglycemia burdens in adults with type 1 diabetes (T1D) using automated insulin delivery (AID) systems.
A quantitative study commissioned by vTv & conducted by dQ&A Market Research examined 674 adults with T1D, finding that 54% of AID users experienced at least one of four hypoglycemia-related burden dimensions.
Among AID users, 24% reported frequent Level 2 hypoglycemia, 12% reported a Level 3 event in the past 12 months, & 17% reported impaired awareness of hypoglycemia.
49% of respondents with an A1C above 7% agreed they often maintain higher blood glucose levels to avoid hypoglycemia or would target lower levels if not for the risk.
Cadisegliatin (TTP399) is an oral, liver-selective glucokinase activator evaluated as a first-in-class adjunctive therapy to insulin for T1D & holds FDA Breakthrough Therapy designation.
Nonclinical studies indicate cadisegliatin increases glucokinase activity independently of insulin to improve glycemic control through hepatic glucose uptake & glycogen storage.
vTv Therapeutics is currently investigating cadisegliatin in a U.S. Phase 3 study, though its safety & efficacy remain unestablished.
The company is a late-stage biopharmaceutical firm focused on oral small molecule candidates for diabetes & other chronic diseases.